Cell-bound complement activation products associate with lupus severity in SLE

Cell-bound complement activation products associate with lupus severity in SLE

Objectives To evaluate the association between lupus severity and cell-bound complement activation products (CB-CAPs) or low complement proteins C3 and C4.Methods All subjects (n=495) fulfilled the American College of Rheumatology (ACR) classification criteria for SLE. Abnormal CB-CAPs (erythrocyte-...

Full description

Saved in:
Bibliographic Details
Main Authors: Richard A Furie, Daniel J Wallace, Judith A James, Susan Manzi, Amit Saxena, Rosalind Ramsey-Goldman, Chaim Putterman, John Conklin, Anca Askanase, Jill P Buyon, Elena Massarotti, Roberta Vezza Alexander, Sonali Narain, Cristina Arriens, Kenneth C Kalunian, Christopher E Collins, Ghalib A Bello, Joseph Ahearn
Format: Article
Language:English
Published: BMJ Publishing Group 2020-10-01
Series:Lupus Science and Medicine
Online Access:https://lupus.bmj.com/content/7/1/e000377.full
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://lupus.bmj.com/content/7/1/e000377.full

Similar Items